| 前收盘价格 | 2.60 |
| 收盘价格 | 2.60 |
| 成交量 | 21,507 |
| 平均成交量 (3个月) | 57,559 |
| 市值 | 78,123,080 |
| 预期市盈率 (P/E Forward) | 11.70 |
| 价格/销量 (P/S) | 15.49 |
| 股市价格/股市净资产 (P/B) | 2.20 |
| 52周波幅 | |
| 利润日期 | 12 May 2025 - 16 May 2025 |
| 营业利益率 (TTM) | -480.61% |
| 稀释每股收益 (EPS TTM) | -0.760 |
| 季度收入增长率 (YOY) | 10.70% |
| 总债务/股东权益 (D/E MRQ) | 6.48% |
| 流动比率 (MRQ) | 5.28 |
| 营业现金流 (OCF TTM) | -21.87 M |
| 杠杆自由现金流 (LFCF TTM) | -11.00 M |
| 资产报酬率 (ROA TTM) | -44.34% |
| 股东权益报酬率 (ROE TTM) | -84.68% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | InspireMD Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.17 |
|
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 17.66% |
| 机构持股比例 | 41.59% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Affiance Financial, Llc | 30 Sep 2024 | 183,746 |
| Nottingham Advisors, Inc. | 30 Sep 2024 | 30,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合